BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability

Abstract Glioblastoma (GBM) is an incurable tumor where temozolomide (TMZ) resistance limits survival, even in MGMT-methylated patients. To improve stratification, we used NAD(P)H-FLIM to profile TMZ response in 35 patient-derived explants, integrating these data with transcriptomic and functional a...

Ausführliche Beschreibung

Gespeichert in:

Bibliografische Detailangaben
Hauptverfasser:	Sara Franceschi, Mariangela Morelli, Francesca Lessi, Francesca Di Lorenzo, Paolo Aretini, Aldo Pastore, Andrea Marranci, Carlo Gambacciani, Francesco Pieri, Federico Villanacci, Nicola Montemurro, Manuel Giacomarra, Michele Menicagli, Gianmarco Ferri, Francesco Pasqualetti, Marco Krengli, Marc Sanson, Alberto Picca, Anna Luisa Di Stefano, Orazio Santo Santonocito, Chiara Maria Mazzanti
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Publishing Group 2026-04-01
Schriftenreihe:	Cell Death Discovery
Online-Zugang:	https://doi.org/10.1038/s41420-026-03112-z
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!

BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability

Ähnliche Einträge